Valuation: Positron Corporation

Market Cap 54.2M 46.45M 43.45M 39.72M 74.96M 5.19B 75.76M 514M 200M 2.61B 203M 199M 8.62B P/E 2024
-11x
P/E 2025 -4.87x
Enterprise Value 53.06M 45.47M 42.54M 38.89M 73.39M 5.08B 74.17M 503M 196M 2.55B 199M 195M 8.44B EV / Sales 2024
49.4x
EV / Sales 2025 116x
Free-Float
45.36%
Yield 2024 *
-
Yield 2025 -
1 day+2.15%
1 week+4.95%
Current month+7.83%
1 month+18.75%
3 months+2.70%
6 months-18.10%
Current year+13.77%
1 week 1.63
Extreme 1.6275
1.91
1 month 1.45
Extreme 1.45
1.91
Current year 1.43
Extreme 1.43
2.74
1 year 1.27
Extreme 1.27
2.74
3 years 0.87
Extreme 0.87
2.94
5 years 0.07
Extreme 0.0682
2.94
10 years 0
Extreme 0
2.94
Manager TitleAgeSince
President 53 27/02/2018
Sales & Marketing - 24/06/2022
Corporate Officer/Principal 40 25/05/2018
Director TitleAgeSince
Chairman 53 -
Director/Board Member - -
Change 5-day change 1-year change 3-year change Capi.($)
+2.15%+4.95%+17.36%+46.15% 55.84M
-0.57%-2.77%-22.15%+0.38% 12.89B
-3.75%-0.15%+21.76%+14.44% 4.7B
-7.64%-7.64%-44.62%-54.58% 1.31B
-3.05%-5.01%-40.11%-36.97% 1.17B
-0.76%-0.95%+19.98%+82.46% 1.12B
-3.37%-14.92%-42.28% - 1.06B
-3.78%-10.27%+42.72%+124.00% 557M
-3.16%-9.54%+45.75% - 301M
-3.43%-4.83%-64.94%+297.83% 257M
Average -2.74%-3.99%-6.65%+59.21% 2.34B
Weighted average by Cap. -2.00%-3.76%-12.33%+9.03%

Financials

2024 2025
Net sales 588K 503K 471K 431K 813K 56.25M 821K 5.57M 2.17M 28.25M 2.21M 2.16M 93.46M 461K 395K 370K 338K 638K 44.19M 645K 4.38M 1.7M 22.19M 1.73M 1.7M 73.41M
Net income -2.38M -2.04M -1.91M -1.74M -3.29M -228M -3.33M -22.57M -8.78M -114M -8.93M -8.74M -378M -10.6M -9.09M -8.5M -7.77M -14.67M -1.02B -14.82M -101M -39.11M -510M -39.81M -38.95M -1.69B
Net Debt 1.42M 1.22M 1.14M 1.04M 1.97M 136M 1.99M 13.51M 5.25M 68.49M 5.35M 5.23M 227M -1.14M -974K -911K -833K -1.57M -109M -1.59M -10.78M -4.19M -54.63M -4.27M -4.17M -181M
Logo Positron Corporation
Positron Corporation is a medical technology company focused to advancing the Positron Emission Tomography (PET) imaging modality through the development, manufacturing, and commercialization of its PET and PET-CT (Positron Emission Tomography/Computed Tomography) imaging systems along with providing comprehensive clinical services to nuclear medicine healthcare providers across North America. The Company specializes in the field of cardiac PET imaging, the gold standard in cardiac diagnostics. The Company’s imaging portfolio includes dedicated PET and 3D PET-CT 64-Slice systems, both designed to expand access to advanced molecular imaging. Additionally, it is preparing to introduce its 4D PET-CT 64-Slice scanner in nuclear cardiology. Its products, Attrius PET and NeuSight PET-CT 64- Slice scanner, provide a molecular imaging solution, enabling healthcare providers with diagnostic accuracy for cardiac and oncologic applications.
Employees
10
Date Price Change Volume
24/08/26 USD 1.650 -2.94% 36,788
21/08/26 USD 1.700 -6.59% 36,409
20/08/26 USD 1.820 +2.25% 8,030
19/08/26 USD 1.780 -1.66% 3,762
18/08/26 USD 1.810 +5.23% 3,600
  1. Stock Market
  2. Stocks
  3. POSC Stock